| AGENUS INC. DL-,01 |
| USA |
| Gesundheit |
| US00847G8042 / A403RK |
| AJ8 (Frankfurt) / AGEN (NASDAQ) |
| FRA:AJ8, ETR:AJ8, AJ8:GR, NASDAQ:AGEN |
| - |
| https://agenusbio.com/ |
|
Agenus Inc. is a clinical-stage biotechnology company focused on discovering and developing immunotherapies to treat cancer and infectious diseases. The company specializes in activating the body's immune system through advanced therapeutic approache..
>Volltext.. |
| 124.32 Mio. EUR |
| 350.8 Mio. EUR |
| 108.44 Mio. EUR |
| 13.3 Mio. EUR |
| 56.56 Mio. EUR |
| 1.52 EUR |
| 266.55 Mio. EUR |
| 30.64 Mio. EUR |
| -76.63 Mio. EUR |
| 0.14 |
| 16.54% |
| - |
| - |
| - |
| - |
| - |
| AGENUS |
| 03.07.26 |
|